We are pleased to formally announce that ES Cell International is doing business under a new look, ESI BIO. Over the coming days and weeks, you will notice more changes to our website and business collateral that will reflect and reinforce our new mission and our commitment to serve you. A formal public announcement will be made soon thereafter.
ESI BIO represents our renewed focus on providing high quality stem cell tools to the research community in the quest to bring research to the clinic and treat disease.
ES Cell International, established in 2000 in Singapore and a wholly-owned subsidiary of BioTime, Inc., was the first organization to provide clinical grade embryonic stem cell lines to the world’s research community. Since then, technical advancements in stem cell science have expanded rapidly, opening up exciting new research and clinical opportunities.
ESI BIO will continue its legacy of enabling scientists to move their cell-based research into the clinic by providing an expanding portfolio of innovative research and clinical-grade products that utilize the latest technical advancements in stem cell science.